ERIN WORTH: Open Payments
NPI 1457505687 · CLACKAMAS, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$794 in 27 payments from 12 companies in 2025. Trend: 2023 $1,095 · 2024 $667 · 2025 $794
Food & beverage: $794
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 7 | $260 |
| Regeneron Healthcare Solutions, Inc. | 7 | $197 |
| Janssen Biotech, Inc. | 1 | $92 |
| Novartis Pharmaceuticals Corporation | 3 | $57 |
| GENZYME CORPORATION | 1 | $40 |
| ABBVIE INC. | 2 | $40 |
| UCB, Inc. | 1 | $31 |
| Biofrontera Inc. | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
Products named: DUPIXENT, NEMLUVIO, TREMFYA, COSENTYX, Bimzelx, AKLIEF, SKYRIZI, AMELUZ.
Industry payments across OR — which companies pay providers there.
